dihexa raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-30. Anything still debated is marked as such rather than presented as settled.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
== Composition == Royal jelly is 67% water, 12.5% protein, 11% simple sugars (monosaccharides), 6% fatty acids and 3.5% 10-hydroxy-2-decenoic acid (10-HDA). It also contains trace minerals, antibacterial and antibiotic components, pantothenic acid (vitamin B5), pyridoxine (vitamin B6) and trace amounts of vitamin C, but none of the fat-soluble vitamins: A, D, E or K.
The molar mass M(X) of atoms of an element X is given by the relative atomic mass Ar(X) of the element multiplied by the molar mass constant, Mu, which (for all practical purposes) is equal to 1 g/mol: M(X) = Ar(X) ⋅ Mu. For normal samples from Earth with typical isotope composition, the atomic weight can be approximated by the standard atomic weight or the conventional atomic weight.
=== October 2009 === In 2009, an additional 21 color photographs surfaced, showing prisoners in Afghanistan and Iraq being abused by their U.S. captors. The American Civil Liberties Union (ACLU) said, "[T]he government had long argued that the abuse at Abu Ghraib was isolated and was an aberration. The new photos would show that the abuse was more widespread." President Barack Obama initially indicated he would not fight the release of the photographs, but "reversed course in May and authorized an appeal to the high court." "The Obama administration believe[d] giving the imminent grant of authority over the release of such pictures to the defense secretary would short-circuit a lawsuit filed by the American Civil Liberties Union under the Freedom of Information Act." On Oct 10, 2009 the US "Congress [was] set to allow the Pentagon to keep new pictures ... from the public"
Sources: en.wikipedia.org
A Gewald aminothiophene synthesis between 4-nitrophenylacetone [5332-96-7] (1) and ethyl cyanoacetate [105-56-6] (2) in the presence of sulfur and triethylamine to give an aminothiophene [174072-89-0]. The amino group was protected with cathyl chloride to give the corresponding carbamate, [308831-93-8] (3). Alkylation with 2,6-Difluorobenzyl chloride [697-73-4] (4) gave [308831-94-9]. Next, a free-radical bromination gave [308831-95-0] (5). Displacement of the bromide with (2-methoxyethyl)(methyl)amine [38256-93-8] (6) and subsequent catalytic hydrogenation of the nitro group gave PC53388810 (7). The aniline was reacted with CDI, and the resulting imidazolide was further treated with methoxyamine [67-62-9] to give the urea [737789-92-3] (8). A cyclization reaction mediated by diethyl pyrocarbonate (DEPC) in the presence of 3-methoxy-6-aminopyridazine [7252-84-8] (9) followed by exposure to sodium methoxide generated thymine derivative [737789-61-6] (10). Quaternization of the basic amine with 1-chloroethyl chloroformate followed by displacement with dimethylamine completed the synthesis of relugolix (11).
== Recalls == In 2018–2019, Teva Pharmaceuticals USA recalled antihypertensive tablets containing valsartan and losartan due to the detection beyond acceptable limit of N-nitrosodiethylamine (NDEA) and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), respectively, which are probable human carcinogens.
According to Wayman, Nagarjuna's explanation is as follows: "the three defilements – nescience, craving, and indulgence – give rise to the two karmas – motivations and gestation – and that these two give rise to the seven sufferings – perception, name-and-form, six sense bases, contact, feelings, re-birth, and old age and death." Vasubandhu's presentation is fully consistent with Nagarjuna's: "nescience, craving, and indulgence are defilement; motivations and gestations are karma; the remaining seven are the basis (asraya) as well as the fruit (phala). As outlined by Wayman, Asanga's Abhidharma-samuccaya divides the nidanas into the following groups:
Myrophine (Myristylbenzylmorphine) is an opiate analogue that was developed in 1952. It is a derivative of morphine. Myrophine is substituted with a 3-benzyl group and a 6-myristyl chain. It is metabolised to form benzylmorphine and then further to morphine, and so is a long-acting prodrug for morphine, but with a slow onset of effects. It is weaker than morphine as an analgesic but longer-lasting in effects, and was thought to have more local anesthetic effect than morphine, though with a somewhat greater tendency to cause reactions like itching and rash. In addiction studies conducted in human subjects in the 1950s, myrophine did not substitute for morphine in withdrawal, did not produce notable morphine-like effects, and did not produce addiction or dependence regardless of dose or how it was administered. Consequently, it was thought to be useful in treating pain in addicts who were being detoxified from other opioid drugs. It is a Schedule I drug in the US, considered to have high potential for abuse and no medical applications, and is controlled under international drug conventions. Myrophine is almost invariably used as the hydrochloride (free base conversion ratio 0.94) and has a DEA Administrative Controlled Substance Control Number of 9308. Myrophine is a Class A controlled substance in the UK, and is on the UN's Yellow list.
Sources: en.wikipedia.org
Methylenedioxypyrovalerone (MDPV) is a psychoactive drug with stimulant properties that acts as a norepinephrine–dopamine reuptake inhibitor (NDRI). It was first developed in the 1960s by a team at Boehringer Ingelheim. MDPV remained an obscure stimulant until around 2004, when it was reported to be sold as a designer drug. Products labeled as bath salts containing MDPV were previously sold as recreational drugs in gas stations and convenience stores in the United States, similar to the marketing for spice and K2 as incense. Incidents of psychological and physical harm have been attributed to MDPV use.
=== Cell extract–based === Nobel Prize winner Eduard Buchner was arguably the first to present a cell-free system using yeast extracts, but since then alternative sources have been found. E. coli, wheat germ, and rabbit reticulocytes have all proven useful to create cell-free systems by extraction of their interior components. E. coli 30S extracts have been acquired, for example, by grinding the bacteria with alumina, followed by further cleaning. Similarly, wheat germ has been ground with acid-washed sand or powdered glass to open the cell membranes up. Rabbit reticulocytes have been lysed in a solution of MgCl2 and had the extract filtered away from the membranes by centrifugation.
Vorster, unwilling to risk incurring the same international and domestic political fallout associated with Operation Savannah, repeatedly rejected Botha's proposals. Nevertheless, the Ministry of Defence and the SADF continued advocating air and ground attacks on PLAN's Angolan sanctuaries.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.